TRAUMA · Jun 24, 2026
Fracture prevention in osteoporosis and nephrolithiasis: maintaining the balance of mineral metabolism
By Nishkumay O, Iaremenko OB, Кondratiuk VY et al.
Background. Fractures remain a leading cause of morbidity worldwide, with hip fractures carrying high mortality and socioeconomic impact. Osteoporosis — driven by reduced bone mineral density — represents a primary risk factor for fractures. Emerging evidence highlights the role of secondary causes of impaired bone remodeling, including endocrine disorders, renal dysfunction, and disturbances in mineral metabolism. Aligned metabolic pathways involving calcium, phosphate, parathyroid hormone (PTH), vitamin D, and fibroblast growth factor-23 (FGF23) link osteoporosis with nephrolithiasis. The purpose was to emphasize the importance of an integrated clinical approach for early detection and prevention of both osteoporosis and kidney stone disease, focusing on primary laboratory monitoring of ionized calcium, phosphorus, PTH, vitamin D and — where feasible — FGF23; to provide recommendations for safe supplementation and targeted specialist referral. Materials and methods. Narrative synthesis of recent evidence (2022–2026) regarding shared risk factors for osteoporosis and nephrolithiasis, including hypercalciuria, hypercalcemia, secondary and primary hyperparathyroidism, and the role of FGF23 in mineral metabolism regulation. Results. Insufficient dietary calcium stimulates secondary hyperparathyroidism, contributing to bone loss and hypercalciuria. Hypercalciuria is associated with reduced bone mineral density in stone formers and higher fracture incidence. Vitamin D is essential for calcium homeostasis, but excessive supplementation may increase urinary calcium excretion in predisposed individuals. Interactions between PTH and FGF23 are central to mineral balance, especially in chronic kidney disease, promoting maladaptive endocrine responses that worsen both skeletal and renal pathology. Conclusions. Osteoporosis and nephrolithiasis should be viewed as manifestations of systemic mineral metabolism dysregulation. A unified clinical framework centered on comprehensive laboratory evaluation, cautious calcium and vitamin D supplementation (preferably calcium citrate in patients at risk of developing kidney stones), and timely referral for hyperparathyroidism can improve prevention of both fractures and nephrolithiasis. Personalized strategies targeting endocrine mediators are essential to reduce the burden of these interconnected conditions.
doi.org/10.22141/1608-1706.3.27.2026.1086Open accessInterventions